STERIS plc (NYSE: STE) reported total revenue of $1.5 billion for the first quarter of fiscal 2027, representing a 7% increase compared to $1.4 billion in the same period of fiscal 2026. Constant currency organic revenue growth stood at 6%. The results were driven primarily by the Healthcare segment, which saw an 8% revenue increase, fueled by gains in consumables and services. Net income for the quarter was $200.1 million, or $2.04 per diluted share, up from $177.4 million, or $1.79 per diluted share, in the prior year’s first quarter.

The company’s Board of Directors oversees these financial disclosures, which include non-GAAP measures such as adjusted net income and free cash flow to provide transparency into core operational performance. Adjusted net income for the quarter was $253.4 million, or $2.59 per diluted share, compared to $231.2 million, or $2.34 per diluted share, in the previous year. The filing notes that these adjusted measures exclude items such as amortization of intangible assets, acquisition-related costs, and restructuring charges, offering a clearer view of underlying business trends.

Segment Performance

The Healthcare segment remained the primary growth engine, with revenue rising 8% to $1.05 billion from $974.7 million in the prior year. This growth was underpinned by a 10% increase in service revenue, 9% growth in consumable revenue, and a 1% rise in capital equipment revenue. Operating income for the Healthcare segment increased to $260.2 million from $235.5 million, driven by improved volume, price, productivity, and favorable mix, though partially offset by inflation and tariff costs.

Applied Sterilization Technologies (AST) revenue grew 6% to $297.6 million, with service revenue up 6% but capital equipment revenue declining 13%. Operating income for AST rose to $142.9 million from $136.7 million, reflecting improved pricing despite higher depreciation and labor costs. Life Sciences revenue increased 9% to $146.7 million, led by a 17% surge in capital equipment revenue. Operating income for this segment climbed to $61.8 million from $58.7 million.

Cash Flow and Restructuring

Net cash provided by operations decreased to $367.1 million from $420.0 million in the prior year, while free cash flow fell to $279.6 million from $326.5 million. This decline was primarily due to a lower contribution from working capital, partially offset by higher net income. Concurrently, STERIS announced a targeted restructuring plan associated with a new Formulated Chemistries Center of Excellence in North Carolina. The plan involves closing facilities in St. Louis, Missouri, and Plymouth, Minnesota, with expected pre-tax charges of $55 million to $70 million, including $40 million to $50 million in cash expenditures.

What the Numbers Show

The divergence between top-line growth and cash flow performance warrants attention. While revenue and net income both increased significantly year-over-year, operating cash flow declined by approximately 12.6%. This suggests that working capital dynamics, rather than operational profitability, are currently driving cash generation. Additionally, the Healthcare segment’s ability to grow operating income despite inflationary pressures and tariff costs indicates strong pricing power and productivity improvements, which may offset broader macroeconomic headwinds.

Outlook

STERIS reiterated its fiscal 2027 guidance, projecting as-reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%. Adjusted earnings per diluted share are expected to be in the range of $11.10 to $11.30. However, capital expenditure guidance was raised to approximately $450 million from $375 million, reflecting investment in the new North Carolina facility. Consequently, full-year free cash flow guidance was lowered to approximately $800 million from $850 million.

Steris has widened its fiscal year 2027 adjusted earnings per share (EPS) guidance while affirming its GAAP EPS outlook, signaling cautious optimism amid stable revenue expectations. The company lowered the floor of its adjusted EPS range from $11.10 to $11.00, maintaining the ceiling at $11.30. Simultaneously, Steris reaffirmed its GAAP EPS guidance at $9.00 to $9.20, which sits slightly below the $9.08 analyst estimate. This dual update provides a clearer picture of profitability expectations, distinguishing between non-GAAP adjustments and standard accounting metrics.

The procedural update reflects a strategic recalibration of financial targets without altering top-line ambitions. Steris affirmed its FY2027 sales guidance at $6.352 billion to $6.411 billion, unchanged from previous communications. This stable revenue outlook contrasts with the widened adjusted earnings band, suggesting that the adjustment stems from margin pressures or cost volatility rather than demand weakness. The company’s decision to maintain its sales projection indicates confidence in its core business operations despite broader economic uncertainties.

Guidance Adjustments

The revision in EPS guidance highlights a cautious stance on bottom-line performance. By widening the range, the company acknowledges potential variability in operating results. The specific metrics disclosed are as follows:

The sales guidance remains aligned with the $6.371 billion analyst estimate, indicating consensus on revenue generation. However, the EPS widening introduces a buffer against unforeseen expenses or operational inefficiencies that could impact net income. The affirmation of GAAP EPS suggests that core operational profitability remains intact, even if non-GAAP adjustments face headwinds.

What the Numbers Show

The decoupling of revenue stability and earnings uncertainty is a key analytical observation. While the top-line forecast remains firm, the downward shift in the adjusted EPS floor suggests that gross margins or operating leverage may face headwinds. Investors should note that the revised adjusted EPS range now spans a wider variance, with the lower bound dropping by $0.10. This structural change in guidance implies that management is prioritizing accuracy over optimism, potentially reflecting broader macroeconomic risks or supply chain costs affecting the sector. The alignment of GAAP EPS with analyst estimates further reinforces the company’s disciplined approach to financial reporting.